Brief: BBOT Granted US FDA Fast Track Designation For BBO-11818 For Treatment of Adult Patients With Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
20/04/2026 22:58
April 20 (Reuters) - BridgeBio Oncology Therapeutics Inc BBOT.O: BBOT GRANTED U.S. FDA FAST TRACK DESIGNATION FOR BBO-11818 FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED KRAS-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA BRIDGEBIO ONCOLOGY THERAPEUTICS INC: UPDATED PHASE 1 CLINICAL DATA ARE EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNXc4lLlc Further company coverage: BBOT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bridgebio Oncology Therapeutics
See all newsBrief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Bridgebio Oncology Therapeutics - May Offer Up To $500 Million In Securities - SEC Filing
Brief: Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
BridgeBio Oncology Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress